1-17 of 17
David C.S. Huang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Thomas E Lew, Mark Van Delft, Chris Riffkin, Georgiou Angela, Christine White, Yin Yuan, Jahja Michelle, Mary Ann Anderson, Rachel Thijssen, David C.S. Huang, Mark A Dawson, Andrew W. Roberts
Journal: Blood
Blood (2023) 142 (Supplement 1): 415.
https://doi.org/10.1182/blood-2023-184392
Published: 2023
Journal Articles

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Rachel Thijssen, Luyi Tian, Mary Ann Anderson, Christoffer Flensburg, Andrew Jarratt, Alexandra L. Garnham, Jafar S. Jabbari, Hongke Peng, Thomas E. Lew, Charis E. Teh, Quentin Gouil, Angela Georgiou, Tania Tan, Tirta M. Djajawi, Constantine S. Tam, John F. Seymour, Piers Blombery, Daniel H.D. Gray, Ian J. Majewski, Matthew E. Ritchie, Andrew W. Roberts, David C.S. Huang
Journal: Blood
Blood (2022) 140 (20): 2127–2141.
https://doi.org/10.1182/blood.2022016040
Published: 2022
Includes: Supplemental data
Journal Articles

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Sylvain Garciaz, Sebastian Müller, Andrew Guirguis, Fiona C. Brown, Yih-Chih Chan, Mathilde Poplineau, Kevin Tran, Kah-Lok Chan, Laura MacPherson, Brian Liddicoat, Enid Y. N. Lam, Tatiana Cañeque, Marian L. Burr, Veronique Litalien, Giovanna Pomilio, Estelle Duprez, David C.S. Huang, Sarah-Jane Dawson, Georg Ramm, Andrew G. Cox, Kristin K. Brown, Andrew H. Wei, Kate McArthur, Raphael Rodriguez, Mark A. Dawson
Journal: Blood
Blood (2021) 138 (Supplement 1): 267.
https://doi.org/10.1182/blood-2021-145424
Published: 2021
Journal Articles

Co-Operation of MCL-1 and BCL-X L Anti-Apoptotic Proteins in Stromal Protection of MM Cells from Carfilzomib Mediated Cytotoxicity

Daria Galas-Filipowicz, Selina J Chavda, Jianan Gong, David C.S. Huang, Asim Khwaja, Kwee Yong
Journal: Blood
Blood (2021) 138 (Supplement 1): 2677.
https://doi.org/10.1182/blood-2021-149160
Published: 2021
Journal Articles

Deep Profiling of Chronic Lymphocytic Leukaemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

Charis E Teh, Tania Tan, Marie Trussart, Mengxiao Luo, Rachel Thijssen, Andrew W Roberts, David C.S. Huang, Terence Speed, Mary Ann Anderson, Daniel Gray
Journal: Blood
Blood (2021) 138 (Supplement 1): 3710.
https://doi.org/10.1182/blood-2021-149938
Published: 2021
Journal Articles

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Donia M Moujalled, PhD, Fiona C Brown, PhD, Giovanna Pomilio, Natasha S Anstee, PhD, Veronique Litalien, Ella R Thompson, PhD BSc, Thomas Morley, Sarah MacRaild, Chong C Chua, MBBS, BMedSc, SéBastien Banquet, PhD, Maia Chanrion, Ana-Leticia Maragno, PhD, Marie Schoumacher, Marco J Herold, PhD, Guillaume Lessene, PhD, Olivier Geneste, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew W Roberts, MBBS, Piers Blombery, MBBS, Andrew Wei, MBBS,PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-136872
Published: 2020
Journal Articles

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Xiangting Chen, PhD, Tamia Nguyen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, John F. Seymour, Constantine S. Tam, MBBS, MD, Michael A Dengler, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew Wei, MBBS,PhD, Andrew W Roberts, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-137775
Published: 2020
Journal Articles

Loss of IRF4 Results in Multiple Myeloma Cell Apoptosis through the Transcriptional up-Regulation of the BH3-Only Proteins Bmf and BIM

Pasquale L. Fedele, MBBS PhDFRACP FRCPA, Yang Liao, PhD, Jianan Gong, PhD, Mark van Delft, PhD, Michael S.Y. Low, MBBS PhDFRACP FRCPA, Lin Tai, PhD, Marco J Herold, PhD, Julie Tellier, PhD, George Grigoriadis, MBBS PhDFRACP FRCPA, David C.S. Huang, MBBS MRCP PhD, Wei Shi, PhD, Stephen Nutt, PhD, Simon Willis, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3103.
https://doi.org/10.1182/blood-2019-126417
Published: 2019
Journal Articles

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Chloe Pek Sang Tang, MBBS, FRACP, Tamia Nguyen, Xing Zhou, Ella Thompson, PhD BSc, Hanzi Sun, Haimei Xing, Bo Zhang, Yin Guo, Lesley Ann Sutton, PhDBSc, Paolo Ghia, MD PhD, Richard Rosenquist, MD PhD, Lydia Scarfo, MD, Silvia Bonfiglio, John F. Seymour, MBBS, PhD FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, David C.S. Huang, MBBS MRCP PhD, Ye Liu, Chan Y. Cheah, David Alan Westerman, MBBS, FRCPA, FRACP, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS, MD, Piers Blombery, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 170.
https://doi.org/10.1182/blood-2019-125488
Published: 2019
Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 171.
https://doi.org/10.1182/blood-2019-125457
Published: 2019
Journal Articles

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Thomas E Lew, Mary Ann Anderson, MBBS, Constantine S. Tam, MBBS, David C.S. Huang, MBBS, MRCP, PhD, Surender Juneja, MD FRCPA, David A Westerman, MBBS, FRACP, FRCPA, John F Seymour, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 3223.
https://doi.org/10.1182/blood.V128.22.3223.3223
Published: 2016
Journal Articles

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

Mary Ann Anderson, MBBS, FRACP, FRCPA, Constantine C.S. Tam, MBBS, FRACP, FRCPA, John F. Seymour, MBBS FRACP, Anthony Bell, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Surender Juneja, MD, David C.S. Huang, MB, BS, MRCP, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2013) 122 (21): 1304.
https://doi.org/10.1182/blood.V122.21.1304.1304
Published: 2013
Journal Articles

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

John F. Seymour, MBBS, FRACP, PhD, Matthew S. Davids, MD, John M. Pagel, MD, PhD, Brad S. Kahl, MD, William G. Wierda, MD, Thomas P. Miller, MD, John F. Gerecitano, MD, PhD, Thomas J. Kipps, MD, PhD, Mary-Ann Anderson, David C.S. Huang, MB, BS, MRCP, PhD, Nikita K. Rudersdorf, Lori A. Gressick, BS, Nicholas P. Montalvo, MBA, CCRP, Jianning Yang, PhD, Todd A. Busman, MS, Martin Dunbar, DRPH, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2013) 122 (21): 872.
https://doi.org/10.1182/blood.V122.21.872.872
Published: 2013
Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

John F. Seymour, MBBS FRACP, Matthew S. Davids, MD, Mary Ann Anderson, PhD, Thomas J. Kipps, MD, PhD, William G. Wierda, MD, PhD, John M. Pagel, MD, PhD, Brad S. Kahl, M.D., Thomas P. Miller, MD, David E. Darden, MS, Cathy E. Nolan, BS, Lori A. Gressick, BS, Hao Xiong, PhD, David C.S. Huang, MB BS MRCP PhD, Brenda J. Chyla, PhD, Todd A. Busman, MS, Alison M. Graham, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2012) 120 (21): 3923.
https://doi.org/10.1182/blood.V120.21.3923.3923
Published: 2012
Journal Articles

The Bcl-2 Protein Family Is Essential for Platelet Survival In Vivo.

Kylie D. Mason, MBBS, Marina R. Carpinelli, PhD, Janelle E. Collinge, PhD, Adrienne A. Hilton, Jamie I. Fletcher, PhD, Andrew W. Roberts, MBBS,PhD, Donald Metcalf, MBBS, David C.S. Huang, MBBS,PhD, Benjamin T. Kile, PhD
Journal: Blood
Blood (2006) 108 (11): 697.
https://doi.org/10.1182/blood.V108.11.697.697
Published: 2006
Journal Articles

The BH3 Mimetic, ABT-737, Is Effective Against Bcl-2 Overexpressing Lymphoid Tumors.

Kylie D. Mason, MD, Cassandra J. Vandenberg, PhD, Mark F. van Delft, B.Sc, Andrew H. Wei, M.D., PhD., Suzanne Cory, B.Sc, PhD, Scott L. Clare, M.D., PhD, Andrew W. Roberts, M.D., PhD, David C.S. Huang, M.D., PhD
Journal: Blood
Blood (2006) 108 (11): 826.
https://doi.org/10.1182/blood.V108.11.826.826
Published: 2006
Journal Articles

Targeting Lymphoid Malignancies with Small Molecule Inhibitors of Pro-Survival Bcl-2 Proteins.

Andrew W. Roberts, MBBS, PhD, Andrew Wei, MBBS, Mark F. van Delft, PhD, Kylie D. Mason, MBBS, Jerry M. Adams, PhD, David C.S. Huang, MBBS, PhD
Journal: Blood
Blood (2005) 106 (11): 1486.
https://doi.org/10.1182/blood.V106.11.1486.1486
Published: 2005